MNKD


MannKind (MNKD): Shoring up the Balance Sheet by Selling Stock Comes with a Price

Shares of biotechnology company MannKind (NASDAQ:MNKD) are taking a hit – down nearly 25% as of this writing. The reason?

This Analyst Sounds the Alarm on MannKind Corporation (MNKD)

What do you do when a company has “more debt than assets?” Maxim’s Jason Kolbert just lost patience with MNKD.

Hedge Fund Tycoon David Shaw Makes 2 Risky Bio Bets: MannKind Corporation (MNKD), Valeant Pharmaceuticals Intl Inc (VRX)

Chief scientist Shaw looks for unusual sources of return in MNKD and VRX.

MannKind Corporation Appoints Dr. David Kendall as Chief Medical Officer

MannKind Corporation (NASDAQ:MNKD), a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for diabetes, today announced the appointment of …

MannKind Corporation: Dilution Is in the Cards

As MannKind spends precious cash, it moves closer to the next capital raise (a.k.

Quant King David Shaw Pours More Money Into Valeant Pharmaceuticals Intl Inc (VRX), MannKind Corporation (MNKD)

One of the world’s top fund managers is backing volatile healthcare stocks VRX and MNKD.

MannKind Corporation (MNKD) CEO Told This Analyst Afrezza’s Revenue Would Build, Not Fall – Q3 Turnout Disappoints

Jason Kolbert recently downgraded MNKD on cash flow concerns; after this Q3 print, looks like he was right.

2 Stocks Under $4 With Upside: Transenterix Inc (TRXC), MannKind Corporation (MNKD)

Both TRXC and MNKD offer potentially big rewards, but at what cost?

MannKind Corporation (MNKD) Shares Slide as Maxim Heads to Sidelines

MannKind’s capital raise is not enough, says Jason Kolbert.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts